Jasper Therapeutics Unveils New Clinical and Preclinical Data on Briquilimab at AAAAI 2025
Redwood City, CA – Jasper Therapeutics, a pioneering biotechnology company, showcased significant progress in the development of briquilimab, an innovative antibody therapy, at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2025 Annual Meeting held in San Diego, CA. The company presented updated findings from the Phase 1b/2a BEACON study and data from four preclinical studies.
Phase 1b/2a BEACON Study Updates
The BEACON study is designed to evaluate the safety, tolerability, and efficacy of briquilimab in patients with chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma. In this latest analysis, Jasper Therapeutics reported that:
- Briquilimab demonstrated a favorable safety profile with no new safety concerns.
- A significant decrease in disease activity was observed in patients with CSU and CIndU, as measured by the weekly urticaria activity score (UAS7).
- Improvements in asthma symptoms, such as forced expiratory volume in one second (FEV1), were also observed.
Preclinical Studies
In addition to the BEACON study updates, Jasper Therapeutics presented data from four preclinical studies:
- Mast cell depletion: Briquilimab effectively depleted mast cells in mice, indicating a mechanism of action for addressing mast cell-driven diseases.
- Efficacy in models of CSU: Briquilimab reduced disease activity and symptoms in CSU models.
- Efficacy in models of asthma: Briquilimab improved airway inflammation and lung function in asthma models.
- Combination therapy: Briquilimab in combination with other therapeutics showed synergistic effects in reducing disease activity in mast cell-driven diseases.
Impact on Individuals
For individuals suffering from chronic mast cell-driven diseases such as CSU and asthma, these findings represent a potential breakthrough in the treatment of their conditions. The data suggests that briquilimab may offer a safe and effective solution for managing symptoms and improving overall quality of life.
Global Implications
The global prevalence of mast cell-driven diseases, including CSU and asthma, is significant. According to the American College of Allergy, Asthma & Immunology, approximately 1-2% of the population experiences CSU, and asthma affects around 235 million people worldwide. The successful development of briquilimab could lead to a major improvement in the lives of millions of people, reducing the burden of these chronic conditions and potentially saving healthcare systems billions of dollars in treatment costs.
Conclusion
Jasper Therapeutics’ presentation at the AAAAI 2025 Annual Meeting provided a comprehensive update on the clinical and preclinical progress of briquilimab, an innovative antibody therapy targeting c-Kit to address mast cell-driven diseases. The data shared highlights the potential for briquilimab to offer a safe and effective solution for individuals suffering from conditions such as CSU and asthma, while also having significant global implications in terms of improving the lives of millions and potentially saving healthcare systems significant costs.
As the development of briquilimab continues, the allergy and immunology community eagerly awaits further updates and potential regulatory approvals, bringing us one step closer to a future where these chronic conditions are better managed and understood.
